ITI announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589 ...
The Washington Business Journal article tells the story of the evolution of Immunomic Therapeutics and its strategy in applying LAMP-Vax in dierent disease areas. The article further highlights Immunomics partnering ...
This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Paragon Bioservices, Inova, University System of Maryland and Medimmune/AstraZeneca. Maryland, Virginia, and Washington, ...
January 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could not ...
TOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that the ...
December 14, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces that C. Eric Winzer, M.B.A., currently serving Immunomic as Chief ...
William Hearl: ‘If we figure out a way to cure a cancer . . . the money will find us’ William Hearl is founder and chief executive officer of Immunomic ...
Announces Issuance of Patent Related to LAMP-Vax™ Technology November 22, 2016 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the ...
THE REMARKABLE SCIENCE BEHIND LAMP TECHNOLOGY – AND ITS POTENTIAL TO TREAT HUMAN DISEASE http://dev.immunomix.com/old/wp-content/uploads/2016/05/Partner_in_Focus_ITI.pdf The body’s own immune system is its best defense against everything from allergies to cancer – ...
Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration On Tues., Nov. 10, Johns Hopkins University and Immunomic Therapeutics, Inc. celebrated the success of the LAMP-Vax platform. The technology ...
-Immunomic Therapeutics to receive upfront payment of $300 million plus 10 percent royalties from potential products for allergic diseases, including peanut allergy- -Immunomic Therapeutics to retain rights of LAMP-vax platform ...
HERSHEY, Pa. and ROCKVILLE, Md., Aug. 28, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that ...